

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL


USAN (KL-04) ZURLETRECTINIB  
PRONUNCIATION zur" le trek' tin ib  
THERAPEUTIC CLAIM Treatment of solid tumors

CHEMICAL NAMES

10*H*-5,7-Ethenopyrazolo[4,3-*g*]pyrido[3,2-*m*]pyrrolo[1,2-*k*][1,4,6,9,11]oxatetraazacyclotetradecin-11(12*H*)-one, 2,18-difluoro-1,2,3,13,14,19*b*-hexahydro-14-methyl-,(2*S*,14*S*,19*bR*)- (Source: CAS)

(1<sup>3</sup>*E*,1<sup>4</sup>*E*,2<sup>2</sup>*R*,2<sup>4</sup>*S*,5*S*)-2<sup>4</sup>,3<sup>5</sup>-difluoro-5-methyl-4-oxa-7,9-diaza-1(5,3)-pyrazolo[1,5-*a*]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclononaphan-8-one (Source: ChemDraw)

STRUCTURAL FORMULA



MOLECULAR FORMULA C<sub>19</sub>H<sub>19</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>  
MOLECULAR WEIGHT 415.40  
TRADEMARK None as yet  
SPONSOR Beijing InnoCare Pharma Tech Co., Ltd.  
CODE DESIGNATIONS ICP-723  
CAS REGISTRY NUMBER 2403703-30-8  
UNII ZVQ44E2H6V  
WHO NUMBER 12433

gbk